Loading...
NAVBQ
OTCM
Market cap0kUSD
Nov 20, Last price  
0.00USD
1D
0.00%
1Q
-99.00%
Jan 2017
-100.00%
Name

Navidea Biopharmaceuticals Inc

Chart & performance

D1W1MN
OTCM:NAVBQ chart
P/E
—
P/S
0.00
EPS
—
Vol. 1Y
2,637.44%
Shs. 5Y
28.73%
Rev. 5Y
-48.49%
Div Yld LY
—
Div Yld TTM
—
Revenues
66k
-87.65%
6,509,9085,952,6405,919,4736,051,0717,124,8117,886,2709,518,03210,700,566597,72978,7381,130,6306,274,84913,249,30721,969,7061,810,437322,52126,618915,013531,51365,652
Net income
-15m
L+29.38%
-1,798,995-3,541,022-4,928,950-4,741,216-5,088,212-5,166,226-39,605,720-49,964,8685,612,992-29,157,204-42,699,458-35,726,669-27,562,680-14,308,38374,946,066-16,126,437-10,945,549-10,721,691-11,730,931-15,177,153
CFO
-9m
L-12.05%
-1,814,435-825,371-3,001,980-3,557,772-1,265,204-3,022,118-1,482,053-5,169,768-16,010,005-23,923,319-35,612,075-29,126,749-19,076,0303,556,78059,083,6064,275,440-9,354,730-8,173,793-10,218,155-8,986,570

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical firm dedicated to advancing and commercializing specialized agents for immunodiagnosis and innovative immunotherapeutics. The company operates across two distinct segments: Diagnostic Substances and Therapeutic Development Programs. Its core technology, the Manocept platform, is designed to target the CD206 mannose receptor, which is prominently found on activated macrophages. This platform enables a variety of diagnostic imaging techniques, including single photon emission computed tomography (SPECT), positron emission tomography (PET), gamma-scanning, and both intra-operative and optical-fluorescence detection methods. Beyond diagnostics, Manocept also facilitates the targeted delivery of therapeutic compounds to macrophages, addressing diseases characterized by immune system involvement and inflammation. Among its key pipeline assets, NAV3-31 has successfully completed Phase IIb clinical trials. These trials assessed the imaging repeatability, reproducibility, and stability, along with the effectiveness of Tc99m tilmanocept imaging in monitoring anti-tumor necrosis factor alpha therapy for patients with moderate to severe rheumatoid arthritis (RA). NAV3-35 is currently undergoing a Phase IIb clinical trial for RA imaging, while NAV3-33 is advancing through Phase III clinical trials, also for RA. Furthermore, NAV3-32 is participating in a Phase 2b trial specifically for RA-involved joints. The company is also exploring the utility of Tc99m tilmanocept in other therapeutic areas, such as cardiovascular conditions, Kaposi's sarcoma, tuberculosis, and various other immunotherapeutic applications. Originally established as Neoprobe Corporation, the company officially adopted the name Navidea Biopharmaceuticals, Inc. in January 2012. Founded in 1983, its corporate headquarters are situated in Dublin, Ohio. In a significant corporate development, Navidea Biopharmaceuticals, Inc. initiated voluntary reorganization proceedings under Chapter 11 with the U.S. Bankruptcy Court for the District of Delaware on October 1, 2025.

Key people

John Scott
Non-Executive Vice Chairman of the Board · since 2021
Craig Dais
Chief Financial Officer, Principal Accounting Officer · since 2023
IPO date
Nov 10, 1992
Employees
11
Domiciled in
US
Incorporated in
US
Legal address
C/O Registered Agent Solutions, Inc.
838 Walker Road, Suite 21-2
Dover, DE 19904
US
Headquarters
4995 Bradenton Avenue
Suite 240
Dublin, OH 43017
US
Previous name
NEOPROBE CORPORATION

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT